AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
- Latest
- Trending
AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Gas fees on the Ethereum network have soared to a multi-month high due to increased transaction volume, causing concern among ...
Analysts predict AI-integrated iPhones could boost Apple's stock and sales, potentially leading to more device replacements and revenue opportunities.
Loop Capital downgrades FMC Corp. to Hold and lowers price target due to inventory challenges in critical markets. Concerns over ...
Bond yields take a breather as the 10-year Treasury backs up. Rate strategists raise concerns while historical trends suggest gains ...
Denny's is expected to report a decline in Q4 revenue, raising concerns among investors. Analysts have revised estimates downward, but ...
The winning momentum trade may be losing steam, according to technical analyst Jonathan Krinsky. The market could experience a turning ...
Evercore ISI maintains "In Line" rating on Fidelity National Information Services (FIS) despite challenges in its Banking Solutions and Capital ...
Guggenheim reaffirms Buy rating on Academy Sports & Outdoors (NASDAQ:ASO) with a price target of $75. The stock has surged ...
JPMorgan remains bullish on Netflix, setting a price target of $610. The investment firm expects accelerated revenue growth and margin ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.